Clinical Trials
23 trialsNCT03412877 2026-05-22
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT02133196 2026-05-13
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT01025089 2026-01-07
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05380713 2025-12-29
......SMARTEST Trial......
University Health Network, Toronto
Phase 2 Completed
NCT03935893 2025-07-10
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Phase 2 Recruiting
NCT03574649 2025-02-21
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT06630611 2025-01-28
PragmaTIL
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT04102436 2024-03-12
Non-Viral TCR Gene Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00828009 2023-07-07
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05816694 2023-04-18
The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03836352 2022-03-31
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2 Active not recruiting
NCT01967823 2021-03-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01909752 2017-07-06
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
UbiVac
Phase 2 Completed
NCT00157209 2015-11-18
Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00157196 2015-08-18
Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00759824 2015-02-12
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
European Lung Cancer Working Party
Phase 2 Completed
NCT00002475 2013-07-10
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00601796 2013-05-24
Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00003943 2013-04-17
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.
Fox Chase Cancer Center
Phase 2 Completed
NCT00083161 2012-09-05
Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Gundersen Lutheran Health System
Phase 2 Completed
NCT00003662 2011-03-07
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases
Roswell Park Cancer Institute
Phase 2 Completed
NCT00003269 2011-01-10
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
Scripps Health
Phase 2 Completed
NCT00089726 2007-12-24
A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)
Cell Genesys
Phase 2 Completed